Reuters: Regulatory News: UPDATE 1-NeurogesX seeks partners for pain drugs

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-NeurogesX seeks partners for pain drugs Apr 17th 2012, 12:26 April 17 | Tue Apr 17, 2012 8:26am EDT April 17 (Reuters) - Pharmaceutical company NeurogesX Inc appointed advisory firm JSB-Partners to help find partners for its neuropathic pain drugs. The U.S. Food and Drug Administration in March declined to approve NeurogesX's Qutenza as a treatment for HIV-related pain. The drug is approved in the United States and Europe as a treatment for pain related to shingles. The setback forced the company to cut 57 percent of its workforce to focus on the development of its most advanced drug candidate, NGX-1998, a liquid formulation of capsaicin, the agent that makes chili peppers hot and is also used in Qutenza. NeurogesX is planning to start a late-stage trial of NGX-1998 in neuropathic pain indication. "We are continuing discussions with partner candidates, who see the value in NGX-1998 and share our vision that NGX-1998 can be a very significant product in the treatment of neuropathic pain," Chief Executive Ronald Martell said in a statement. NeurogesX shares closed at 52 cents on Monday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions